NERV vs NGNE

Minerva Neurosciences, Inc vs Neurogene Inc. — Valuation Comparison 2026

NERV

Pharmaceutical Preparations
Minerva Neurosciences, Inc
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$4.91
Last close
Models
6/13
Active
VS

NGNE

Pharmaceutical Preparations
Neurogene Inc.
Quality
5.2
out of 10
Value Trap
18
SAFE
Price
$28.34
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NERV Fair ValueNERV Upside NGNE Fair ValueNGNE Upside
Bayesian DCF Intrinsic $1.70 -65.3% $11.44 -59.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $16.56 -41.6%
PWERM Option-Based $11.74 +139.1% $27.04 -4.6%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NERV vs NGNE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NERV vs NGNE — Which Stock Is More Undervalued?

NGNE scores higher with a 5.2/10 quality rating vs NERV's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Minerva Neurosciences, Inc (NERV) and Neurogene Inc. (NGNE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NERV currently trades at $4.91 with a QOC of 3.4/10, while NGNE trades at $28.34 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).